Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vermont Tech Scene.
Press releases published on April 28, 2025
Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
GlobeNewswire
·
April 28, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a …
UK Company, Stablepharma Ltd, enters Phase 1 Clinical Trials with world-first Fridge-Free Tetanus & Diphtheria Vaccine
GlobeNewswire
·
April 28, 2025
LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by …
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
GlobeNewswire
·
April 28, 2025
MELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET1 imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide …
Bel Fuse Inc. Announces Regular Quarterly Cash Dividend on its Class A and Class B Shares
GlobeNewswire
·
April 28, 2025
WEST ORANGE, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- BEL FUSE INC. (NASDAQ:BELFA) and (NASDAQ:BELFB) today announced that its Board of Directors has declared regular quarterly cash dividends of $0.06 per share on the Company's Class A common shares and $0 …
ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
– Oral and poster presentations will highlight advancements from ElevateBio’s two business units: Life Edit, its gene editing and R…
VERSES® Announces Closing of US$7.9 Million (C$11.0 Million) Public Offering
GlobeNewswire
·
April 28, 2025
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSF) ("VERSES'' or the "Company”) a cognitive computing company specializing in next-generation intelligent software systems is pleased to announce that the …
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with …
Cellectis présente une approche non virale d’édition du génome et des innovations avec les base editors à l’ASGCT 2025
GlobeNewswire
·
April 28, 2025
NEW YORK, 28 avr. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS - NASDAQ : CLLS) (la "Société"), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome pour développer des thérapies cellulaires …
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion
GlobeNewswire
·
April 28, 2025
Reflects business philosophy of commercial success through patient accessibility Recently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company’s dedicated R&D and manufacturing facility; no impact on shareholder …
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster presentation to feature scalability …
Arbor Biotechnologies to Present Foundational Data for PH1 and CNS Programs at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
- Oral presentation to include preclinical data supporting the clinical advancement of ABO-101 for the treatment of primary hyperoxaluria type 1 - Four poster presentations collectively demonstrate advancement of company’s differentiated CNS gene editing …
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire
·
April 28, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual …
Trident Filed 2024 Annual Report on Form 20-F
GlobeNewswire
·
April 28, 2025
SINGAPORE, April 29, 2025 (GLOBE NEWSWIRE) -- Trident Digital Tech Holdings Ltd (“Trident” or the “Company,” NASDAQ: TDTH), a leading catalyst for digital transformation in technology optimization services and Web 3.0 activation based in Singapore, today …
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
GlobeNewswire
·
April 28, 2025
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate …
Spur Therapeutics Announces Oral and Poster Presentations Highlighting Data from Clinical and Preclinical Programs at Upcoming ASGCT Annual Meeting
GlobeNewswire
·
April 28, 2025
LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that it will share new data from its gene therapy programs in Gaucher disease, GBA1 Parkinson’s disease and adrenomyeloneuropathy in oral and poster presentations at the American …
Axovia Therapeutics Announces Three Upcoming Poster Presentations at ASGCT
GlobeNewswire
·
April 28, 2025
LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, today announced that Co-Founder and Chief Scientific Officer, Dr. Victor Hernandez, …
Shape Therapeutics Announces Multiple Oral and Poster Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
SEATTLE, April 28, 2025 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader in RNA-based gene therapy, today announced the acceptance of multiple abstracts, including two oral presentations, at the upcoming 28th Annual Meeting of the American Society of Gene …
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today …
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
April 28, 2025
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H…
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire
·
April 28, 2025
Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase …